Clive Dix, a serially successful figure in UK biotech, has been appointed chief executive of UK biotech company C4X Discovery Holdings (AIM:C4XD).
Dr Dix joined the ambitious company, which has the aim of becoming the world’s most productive drug discovery and development company, as non-executive chairman in November 2014. A year later he became executive chairman, with previous chief executive Piers Morgan standing down.
With Dr Dix taking on the chief executive role immediately, non-executive director Sam Williams will become interim chairman while the search for a new chairman takes place.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze